Key Quantitative Figures

  • Equity Shares Allotted: 31,37,586 fully paid-up equity shares of face value ₹10 each
  • Convertible Warrants Allotted: 21,45,145 warrants convertible into equity shares
  • Issue Price: ₹36.50 per security (includes premium of ₹26.50)
  • Total Funds Raised from Equity: ₹11,45,21,889 (Eleven Crore Forty-Five Lakh Twenty-One Thousand Eight Hundred Eighty-Nine)
  • Conversion Period for Warrants: 18 months from date of allotment
  • Number of Allottees: 14 for equity shares, 13 for warrants

Dates of Action

  • Board Meeting Date: 29th August 2026 (commenced at 3:30 PM, concluded at 4:00 PM)
  • Stock Exchange Approval: Received in-principal approval on 21st August 2026
  • Disclosure Date: 29th August 2026

Parties Involved

  • Issuer: Parmax Pharma Limited
  • Regulatory Authority: BSE Limited, SEBI
  • Allottee Categories: Non-promoter category members

Capital Structure Impact

Preferential Equity Share Allotment Details:

The equity shares allotted rank pari-passu with existing equity shares of the Company.

Convertible Warrants Terms:

Each warrant convertible into 1 equity share of ₹10 each, exercisable in one or more tranches within 18 months from allotment date. Equity shares allotted upon conversion shall rank pari passu with existing equity shares.

Allottee Details and Ownership Changes

| Allottee Name | Pre-Issue Holding | Shares Allotted | Warrants Allotted | Post-Issue Holding | Post-Issue % | Category Change |

| Dhiren Chandulal Shah | 0 | 604,190 | 535,715 | 1,139,905 | 12.63% | Non-Promoter → Promoter |

| Sunil Chinubhai Shah | 0 | 91,911 | 81,494 | 173,405 | 1.92% | Non-Promoter → Promoter |

| Hiren Pravin Doshi | 0 | 217,508 | 192,857 | 410,365 | 4.55% | Non-Promoter → Promoter |

| Umang Alkesh Gosalia | 200,000 | 342,466 | - | 542,466 | 6.01% | Non-Promoter → Promoter |

| Sheetal Hiren Doshi | 0 | 24,167 | 21,429 | 45,596 | 0.51% | Non-Promoter → Promoter Group |

| Nirmal Sunilbhai Shah | 32,500 | 164,832 | 144,715 | 342,047 | 3.79% | Non-Promoter → Promoter Group |

| Dhairya Dhiren Shah | 0 | 120,838 | 107,143 | 227,981 | 2.53% | Non-Promoter → Promoter Group |

| Rupa Sunil Shah | 0 | 69,206 | 61,363 | 130,569 | 1.45% | Non-Promoter → Promoter Group |

| Vijaykumar Natvarlal Shiyani | 0 | 161,117 | 142,857 | 303,974 | 3.37% | Non-Promoter → Promoter Group |

| Kamlesh Natvarlal Shiyani | 7,500 | 161,974 | 143,286 | 312,760 | 3.47% | Non-Promoter → Promoter Group |

| Abhay Chinubhai Shah | 0 | 322,235 | 285,715 | 607,950 | 6.74% | Non-Promoter → Promoter Group |

| Urvi Manish Kothari | 0 | 285,714 | 142,857 | 428,571 | 4.75% | Non-Promoter → Non-Promoter |

| Mili Saumil Shah | 0 | 285,714 | 142,857 | 428,571 | 4.75% | Non-Promoter → Non-Promoter |

| Fredun Nariman Medhora | 0 | 285,714 | 142,857 | 428,571 | 4.75% | Non-Promoter → Non-Promoter |

Note: Percentage holdings calculated based on post-preferential shareholding assuming full conversion of all warrants to equity shares.

Additional Information

The disclosure includes Annexure I and II providing detailed information as required by SEBI circular on preferential issues. The information is also available on the company website at www.parmaxpharma.com.